AZN.UK

11,322

-0.68%↓

GSK

1,464.5

-0.95%↓

AZN.UK

11,322

-0.68%↓

GSK

1,464.5

-0.95%↓

AZN.UK

11,322

-0.68%↓

GSK

1,464.5

-0.95%↓

AZN.UK

11,322

-0.68%↓

GSK

1,464.5

-0.95%↓

AZN.UK

11,322

-0.68%↓

GSK

1,464.5

-0.95%↓

Search

PureTech Health Plc

Fermé

108.4 -3.04

Résumé

Variation du prix de l'action

24h

Actuel

Min

103.6

Max

111.8

Chiffres clés

By Trading Economics

Revenu

70M

Ventes

4M

P/E

Moyenne du Secteur

9.077

35.664

BPA

-0.19

Marge bénéficiaire

1,727.216

Employés

56

EBITDA

102M

Statistiques du Marché

By TradingEconomics

Capitalisation Boursière

285M

Ouverture précédente

111.44

Clôture précédente

108.4

PureTech Health Plc Graphique

Les performances passées ne sont pas un indicateur fiable des résultats futurs.

Actualités Associées

15 sept. 2025, 22:39 UTC

Acquisitions, Fusions, Rachats

CSL Agrees to Deal to Advance Coagulation Treatment, May Acquire Developer

15 sept. 2025, 16:43 UTC

Principaux Mouvements du Marché

Strive Shares Sink on Board Disclosure; Bitcoin Treasury Strategy

15 sept. 2025, 16:42 UTC

Principaux Mouvements du Marché

Helius Medical Tech Jumps on Funding to Launch Solana Treasury

15 sept. 2025, 16:35 UTC

Principaux Mouvements du Marché

Chegg to Pay $7.5 Million to Settle FTC Claims Over Subscription Cancellation Process

15 sept. 2025, 23:46 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

15 sept. 2025, 23:46 UTC

Market Talk

Nikkei May Rise as Fed Rate Cut Hopes Support Stocks -- Market Talk

15 sept. 2025, 23:34 UTC

Market Talk

Gold Steady Ahead of FOMC Meeting, Major U.S. Economic Data -- Market Talk

15 sept. 2025, 22:48 UTC

Market Talk

FOMC May Opt to Play Catch Up With Rate Cuts -- Market Talk

15 sept. 2025, 22:12 UTC

Acquisitions, Fusions, Rachats

CSL Expects Commercial Launch in 2029

15 sept. 2025, 22:12 UTC

Acquisitions, Fusions, Rachats

CSL Says VarmX to Receive Further Commercial Milestones Afterwards

15 sept. 2025, 22:11 UTC

Acquisitions, Fusions, Rachats

CSL Says VarmX to Receive Payments of Up to $388 Million Up to Launch of VMX-C001

15 sept. 2025, 22:11 UTC

Acquisitions, Fusions, Rachats

CSL to Have Right to Exercise Option Based on Phase 3 Data

15 sept. 2025, 22:10 UTC

Acquisitions, Fusions, Rachats

CSL to Make Upfront Payment to VarmX of $117 Million for Exclusive Option to Acquire Company

15 sept. 2025, 21:16 UTC

Acquisitions, Fusions, Rachats

Chord Energy: Assets Have a Low Avg NYMEX WTI Breakeven and Are Immediately Competitive for Capital

15 sept. 2025, 21:16 UTC

Acquisitions, Fusions, Rachats

Chord Energy: Assets Have Significant Overlap With Existing Footprint, Setting the Stage for Long-Lateral Development

15 sept. 2025, 21:15 UTC

Acquisitions, Fusions, Rachats

Chord Energy to Buy 48,000 Net Acres in the Williston Core

15 sept. 2025, 21:14 UTC

Acquisitions, Fusions, Rachats

Chord Energy to Buy Assets in Williston Basin From Exxon's XTO Energy and Affiliates for $550M

15 sept. 2025, 20:50 UTC

Market Talk

Auto & Transport Roundup: Market Talk

15 sept. 2025, 20:50 UTC

Market Talk

Financial Services Roundup: Market Talk

15 sept. 2025, 20:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

15 sept. 2025, 19:29 UTC

Market Talk

U.S. Natural Gas Gains on Warmer Weather Outlook -- Market Talk

15 sept. 2025, 19:14 UTC

Market Talk

Attacks on Russia Lifts Oil Price Despite Shaky Fundamentals -- Market Talk

15 sept. 2025, 18:16 UTC

Market Talk

Gold Powers to New High -- Market Talk

15 sept. 2025, 18:05 UTC

Market Talk

Easing Autonomous Vehicle Regulations Will Begin Tesla's Next Chapter -- Market Talk

15 sept. 2025, 17:50 UTC

Acquisitions, Fusions, Rachats

U.S. Reaches Outline of Deal With China Over TikTok -- 2nd Update

15 sept. 2025, 17:10 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

15 sept. 2025, 17:10 UTC

Market Talk

S&P Expects Fed, BOC to Cut Rates -- Market Talk

15 sept. 2025, 16:52 UTC

Market Talk

Copper Climbs as Traders Brace for U.S. Rate Cut -- Market Talk

15 sept. 2025, 16:20 UTC

Market Talk

Financial Services Roundup: Market Talk

15 sept. 2025, 16:20 UTC

Market Talk
Résultats

Auto & Transport Roundup: Market Talk

Comparaison

Variation de prix

PureTech Health Plc prévision

Note du Consensus

By TipRanks

0 ratings

0

Achat

0

Maintien

0

Vente

Éléments financiers

Frais Généraux et Administratifs

Dépenses d'exploitation

Résultat avant impôt

Ventes

Coût des ventes

Marge brute des ventes

Charges d'intérêt sur la dette

EBITDA

Bénéfice d'exploitation

$

À Propos PureTech Health Plc

PureTech Health plc, engages in the development and commercialization of biotechnology and pharmaceutical solutions in the United States. The company is developing LYT-100, which is under Phase 2 stage, to treat idiopathic pulmonary fibrosis (IPF); and LYT-200, a IgG4 monoclonal antibody, currently under Phase 1/2 stage, targeting galectin-9 for treating solid tumors and hematological malignancies. It also develops SPT-300, an oral drug of allopregnanolone for the treatment of anxious depression; SPT-320, a novel prodrug of agomelatine for the treatment of generalized anxiety disorder; and SPT-348, a prodrug of a non-hallucinogenic neuroplastogen for the treatment of mood and other neuropsychiatric disorders. In addition, the company is developing hydrogels to enable the oral administration of peptide therapeutics in preclinical development. The company was incorporated in 2015 and is headquartered in Boston, Massachusetts.
help-icon Live chat